Literature DB >> 16530413

Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors.

Jin Hee Ahn1, Seung Jun Kim, Woul Seong Park, Sung Yun Cho, Jae Du Ha, Sung Soo Kim, Seung Kyu Kang, Dae Gwin Jeong, Suk-Kyeong Jung, Sang-Hyeup Lee, Hwan Mook Kim, Song Kyu Park, Ki Ho Lee, Chang Woo Lee, Seong Eon Ryu, Joong-Kwon Choi.   

Abstract

A series of rhodanine derivatives was synthesized and evaluated for their ability to inhibit PRL-3. Benzylidene rhodanine derivative showed good biological activity, while compound 5e was the most active in this series exhibiting an IC50 value of 0.9 microM in vitro and showed a reduced invasion in cell-based assay.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16530413     DOI： 10.1016/j.bmcl.2006.02.060

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  25 in total

Review 1.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

2.  Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility.

Authors:  Mark W Zimmerman; Kelley E McQueeney; Jeffrey S Isenberg; Bruce R Pitt; Karla A Wasserloos; Gregg E Homanics; John S Lazo
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

3.  Testing the ability of rhodanine and 2, 4-thiazolidinedione to interact with the human pancreatic alpha-amylase: electron-density descriptors complement molecular docking, QM, and QM/MM dynamics calculations.

Authors:  Rajendran Niranjana Devi; Maria G Khrenova; Samuel Israel; Chellam Anzline; Andrey A Astakhov; Vladimir G Tsirelson
Journal:  J Mol Model       Date:  2017-08-05       Impact factor: 1.810

Review 4.  Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.

Authors:  Michihiro Kobayashi; Sisi Chen; Rui Gao; Yunpeng Bai; Zhong-Yin Zhang; Yan Liu
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

5.  Photooxygenation of an amino-thienopyridone yields a more potent PTP4A3 inhibitor.

Authors:  Joseph M Salamoun; Kelley E McQueeney; Kalyani Patil; Steven J Geib; Elizabeth R Sharlow; John S Lazo; Peter Wipf
Journal:  Org Biomol Chem       Date:  2016-07-06       Impact factor: 3.876

Review 6.  The role and target potential of protein tyrosine phosphatases in cancer.

Authors:  Taolin Yi; Daniel Lindner
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

Review 7.  Targeting PTPs with small molecule inhibitors in cancer treatment.

Authors:  Zhong-Xing Jiang; Zhong-Yin Zhang
Journal:  Cancer Metastasis Rev       Date:  2008-06       Impact factor: 9.264

8.  PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy.

Authors:  Jianbiao Zhou; Chonglei Bi; Wee-Joo Chng; Lip-Lee Cheong; Shaw-Cheng Liu; Sylvia Mahara; Kian-Ghee Tay; Qi Zeng; Jie Li; Ke Guo; Cheng Peow Bobby Tan; Hanry Yu; Daniel H Albert; Chien-Shing Chen
Journal:  PLoS One       Date:  2011-05-12       Impact factor: 3.240

9.  Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer.

Authors:  Akira Ooki; Keishi Yamashita; Shiro Kikuchi; Shinichi Sakuramoto; Natsuya Katada; Mina Waraya; Hiroshi Kawamata; Hiroshi Nishimiya; Kazunori Nakamura; Masahiko Watanabe
Journal:  BMC Cancer       Date:  2011-04-06       Impact factor: 4.430

10.  Phosphatase of regenerating liver-3 directly interacts with integrin β1 and regulates its phosphorylation at tyrosine 783.

Authors:  Wei Tian; Like Qu; Lin Meng; Caiyun Liu; Jian Wu; Chengchao Shou
Journal:  BMC Biochem       Date:  2012-10-23       Impact factor: 4.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.